1 / 23

Medsafe – GMP update / release for supply / communicating quality issues

Medsafe – GMP update / release for supply / communicating quality issues. Derek Fitzgerald Manager, Compliance Management. 11 July 2013 RACI Pharmaceutical Science Group (NSW). Medsafe and GMP. Medsafe – an introduction GMP update Release for supply – New Zealand

wayde
Download Presentation

Medsafe – GMP update / release for supply / communicating quality issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical Science Group (NSW)

  2. Medsafe and GMP • Medsafe – an introduction • GMP update • Release for supply – New Zealand • Communicating quality issues

  3. Medsafe • The New Zealand Medicines and Medical Devices Safety Authority • Relevant legislation – Medicines Act 1981, Medicines Regulations 1984 • Comprises several ‘Branches’ • Compliance Management • Product Regulation • Clinical Risk Management 3

  4. CMB – area of operation • GMP audit and licensing / certification • Medicines and medical devices complaints & recalls • Investigations and prosecutions • Medicines testing programme • Medical devices listing database (WAND) • Advertising complaints and issues • Advice on legislation and policy • Legislative compliance • Border control 4

  5. CMB Teams • Product Safety (Wellington) (8 staff) • Post-market complaints, recalls & market actions • GMP • Medicines testing programme • Medical devices – WAND • Advertising issues • Supply of unapproved products • Investigations & Enforcement Team (Auckland) (5 staff) • Investigations and prosecutions • Border control and importation 5

  6. Some post-market statistics For the full financial year: Jul 2012 – Jun 2013 • Medicines incidents handled / closed: 478, of which 29 were recalls • Medical devices incidents handled / closed: 1,067, of which 284 were recalls or market actions • GMP audits conducted: 49 • Packages inspected at the border: 11,500 6

  7. The New Zealand GMP Scene • Currently around 50 ‘active’ sites • Wide range of manufacturing operations • 8 API – including clinical trials, biologicals • 10 complementary medicines • 8 blood service or similar • 5 gas sites • 2 overseas • 4 testing laboratories • 10 packing sites 7

  8. GMP operations • Medsafe performs around 50 audits annually with 3 auditors (recent increase) • Audit frequency is determined through risk assessment performed at each audit • Various mechanisms used to ensure resolution of GMP issues is achieved • Ongoing interaction and follow up is common • Growing requirement for advice on post-market issues 8

  9. GMP developments • Now a PIC/s member • ANZTPA B2B – B4 • Information sharing • Joint training • Joint audits • Future alignment of processes • Closer relationship with TGA • Application to EU in respect of API third country exemption status 9

  10. ANZTPA • Intention of both Governments to proceed with the establishment of a joint agency • Key points – Joint Agency, new / updated legislation (especially for New Zealand) • Work is underway on planning the establishment process • Currently NZ and Australia are closely aligned with respect to Good Manufacturing Practice 10

  11. Trans-Tasman GMP relationship • Over 2 decades of cooperation • Close GMP alignment • Strong relationship build up to ANZTPA #1 • Being a competent and credible small GMP regulator requires close relationships and cooperation with others • Looking forward to a continuing and growing relationship 11

  12. Release for supply in NZ - overview • Legislative requirements • Licensing of ‘sponsors’ • Issues noted • GMP / contractual arrangements • Process 12

  13. Legislative requirements • Sale of a medicine • Requirement to be licensed • Section 42 – specifications and testing • Sections 20 and 24 – product approval • Recall and other market actions (regulation 50) 13

  14. Licensing of sponsors • Licence to Sell Medicines by Wholesale • Audits carried out by Ministry of Health • Monitoring of compliance through interactions during quality investigations / recalls 14

  15. Issues noted • Stock imported and distributed when not for the NZ market • Failure to meet current approved specifications • Off-shore actions creating liability in NZ • Failure to understand responsibility • Need to fully understand products, GMP / technical issues and legal issues 15

  16. Contractual arrangements • Distribution chain can be complex • Need to ensure technical arrangements are met and responsibility clear • Flexible – several models of operation accepted 16

  17. Process summary • A licensed NZ entity responsible for market release • NZ approved product details are held • Stock is received into quarantine • C of A is received and compared with approved details • Batch is identified and labelling is examined • Release can be made 17

  18. Communicating quality issues • Responding to the regulator • Responding to a market issue • Dealing with issues successfully • Response is important and determines the level of confidence a regulator can have in a manufacturer / sponsor 18

  19. Responding to quality issues - when the regulator has questions • Ensuring a clear line of communication between manufacturing site / NZ sponsor / Medsafe • The NZ sponsor is legally responsible • Rapid response is required – even if full answers may take time • Risk assessment based on product knowledge – important • Effective action in the distribution chain 19

  20. Responding to market quality issues • How is a quality complaint received? • Who is involved in making early decisions? • Ensure rapid risk assessment • Systems should be integrated – production, marketing, distribution, clinical, QA • How will decisions be made? 20

  21. Regulatory expectations • Medsafe has the expertise to understand your explanation • We are looking for you to demonstrate competence in handling issues • We look at what you send and assess it • Important to be consistent • Be honest • Ensure all questions are answered 21

  22. A good technical response • There should be a clear description of the problem • Describe the investigation so far • Ensure clinical assessment is provided, if appropriate • Distribution details are important • Identify the possible manufacturing issues • Be clear about testing performed / planned • Provide rationale for possible explanations and for ruling out possibilities 22

  23. Thank you • Contact details: • Medsafe website: www.medsafe.govt.nz • Email contacts for specific questions • GMP: askmedsafe@moh.govt.nz • Product Safety Team: recalls@moh.govt.nz 23

More Related